• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
By STEVE GELSI Jun 26, 2018 | 03:24 PM EDT
Stocks quotes in this article: GWPH, NMUS, ZYNE, INSY

With GW Pharmaceuticals (GWPH) approaching the U.S launch of its long-awaited Epidiolex epilepsy medicine, the space for cannabis-based drugs to treat the disorder and other maladies is finally moving into reality.

London-based GW Pharma said Monday (June 25) the U.S. Food and Drug Administration (FDA) has approved Epidiolex, a cannabinoid-based oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome -- both rare forms of epilepsy -- in patients at least two years old.

This milestone effectively brightens the spotlight on GW Pharma and at least three other stocks -- Nemus Bioscience (NMUS) , Zynerba Pharmaceuticals (ZYNE) and Insys Therapeutics (INSY) -- as companies developing medicines derived from marijuana.

"This decision sets a precedent for other companies seeking to bring to market a cannabis-based product," said Matt Karnes founder and managing partner, GreenWave Advisors, a New York-based legal cannabis research firm. "It bodes well for Nemus, Zynerba and Insys."

For the most part, the cannabis stories on these stocks have been well known to investors. So when the news broke about the FDA approval, GW Pharma shares dropped along with overall weakness in equities during the session on Monday.

In Tuesday trading, GW Pharma was up 1.2% to $146.51, Nemus Bioscience traded about flat at $0.28, Zynerga Pharma rose 4% to $10.92 and Insys Therapeutics dropped 2.4% to $7.72.

One bureaucratic hurdle remains for Epidiolex, however. While CBD has no psychoactive properties, it is still derived from marijuana, which remains classified as a Schedule 1 drug under federal law, with no therapeutic or medicinal attributes.

GW Pharmaceuticals said it expects federal authorities to de-schedule Epidiolex within 90 days.

Speaking to this process, Karnes said Epidiolex calls to question the suitability of current DEA scheduling of cannabis as a drug with no health benefits."The approval of Epidiolex contradicts the negative longstanding view and will likely prompt pressure for a change to the current DEA scheduling," Karnes said.

A DEA spokesperson did not return a phone call from Real Money.

With cannabis-based pharmaceuticals now approaching commercialization, investors will likely be hearing more from these companies:

GW Pharma

As a specialist in marijuana-derived medicines for forms of epilepsy and other illnesses, London-based GW Pharma has had an eye on the U.S. market shortly after its inception 19 years ago.

It has been working on the launch of Epidiolex for years, culminating in successful Phase 3 trials of the drug in 2016.

GW Pharma has already commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, for the treatment of spasticity due to multiple sclerosis. It is now sold in numerous countries outside the U.S.

Looking ahead, GW Pharma is planning a U.S. Phase 3 trial for Sativex, along with a pipeline of cannabinoid product candidates, which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

For now, while GW Pharma generates some revenue, the company has not yielded any net income. However, it is well capitalized for the launch of Epidiolex and other products via $260 million it raised in a December offering of American Depositary Shares.

Nemus Bioscience

A tiny company with a market cap of $38 million, Nemus Bioscience offers an interesting story but no revenue as of yet.

The Costa Mesa, Calif company plans to develop and sell therapeutic medicine from cannabis through a partnership with the University of Mississippi, a federally permitted and licensed cultivation facility for research and commercial applications of pot.

The company has been operating since 2014 under three licensing agreements with the university for UM 5050, a formulation of THC, and other drugs.

In February, investment firm Emerald Health Sciences Inc. closed a $1.75 million private placement in Nemus Bioscience, to support its efforts to develop treatments for glaucoma and dry eye syndrome.

Insys Therapeutics

In recent months, Insys has shifted from a focus on opioids medicines to cannabinoids.

It is currently conducting Phase 3 trials on CBD medicines to treat infantile spasm, as well as Phase 2 trials for childhood absence epilepsy and Prader-Willi syndrome. It is also collaborating on autism research with UC San Diego's Center for Medicinal Cannabis Research.

Insys is considering research partnerships on addiction, childhood schizophrenia and post-traumatic stress disorder. It also sells Subsys, an opioid-based pain medication for cancer patients.

In its most recent quarter, Insys rang up a net loss of $20 million and revenue of $23.9 million. At last check, its market cap totaled about $583 million.

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals continues to develop transdermal cannabinoid treatments for rare neurological and psychiatric disorders.

Its lead product candidate is ZYN002 transdermal CBD gel, currently in Phase 2 studies in patients with developmental and epileptic encephalopathies. It is also preparing a single pivotal trial for Fragile X syndrome, an inherited syndrome that may result in mental handicap.

Last month, it announced it remained on track to launch the Fragile X syndrome trial in the middle of this year to support a new drug application filing with the FDA.

The company reported it holds $52.1 million in cash as of March 31. It's enough to fund operations and capital requirements into 2019, the company said last month.

At last check, Zynerba's market cap stood at $148 million.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gelsi had no positions in any securities mentioned.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider NMUS to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

TAGS: Investing | U.S. Equity | Regulation | Markets | Cannabis | Healthcare | Stocks

More from Healthcare

Let's Take a Look at Elevance Health Ahead of Earnings

Bruce Kamich
Jan 24, 2023 3:00 PM EST

What are chart patterns indicating?

Moderna Shares Surge on Promising Vaccine Results

Bruce Kamich
Jan 18, 2023 11:02 AM EST

Let's check the charts and indicators.

This Pharma Presents a Potential 'Lose-Win' Situation for Patients and Investors

Brad Ginesin
Jan 7, 2023 7:00 AM EST

Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.

Walgreens Could Continue to Weaken

Bruce Kamich
Jan 5, 2023 12:56 PM EST

The company reported earnings and the shares have rolled over and turned down.

NovoCure Gaps Sharply Higher for a Breakout: How to Play It

Bruce Kamich
Jan 5, 2023 11:26 AM EST

Let's check out the charts and indicators of both NovoCure and Zai Lab.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:27 PM EST REAL MONEY

    LIVE EVENT: Chris Versace and "Sarge" Guilfoyle Share Their Stock Market Insights

    This Monday, Jan. 30, at 12 p.m., our very own exp...
  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login